Reduction of 99mTc-sestamibi and 99mTc-tetrofosmin uptake in MRP-expressing breast cancer cells under hypoxic conditions is independent of MRP function

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 11, 2003, Pages 1529-1531

  Kinuya, Seigo ^a   Li, Xiao Feng ^a   Yokoyama, Kunihiko ^a   Mori, Hirofumi ^b   Shiba, Kazuhiro ^b   Watanabe, Naoto ^c   Shuke, Noriyuki ^d   Bunko, Hisashi ^e   Michigishi, Takatoshi ^a   Tonami, Norihisa ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d ASAHIKAWA MEDICAL COLLEGE   (Japan)

^e KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

99mTc sestamibi; 99mTc tetrofosmin; Hypoxia; Multi drug resistance associated protein

Indexed keywords

CARBON DIOXIDE; IODINE 125; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NITROGEN; PROTEIN ANTIBODY; TETROFOSMIN TC 99M; DIAGNOSTIC AGENT; ORGANOPHOSPHORUS COMPOUND; OXYGEN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M 1,2 BIS(BIS(2 ETHOXYETHYL)PHOSPHINO)ETHANE; TECHNETIUM TC 99M 1,2-BIS(BIS(2-ETHOXYETHYL)PHOSPHINO)ETHANE; TUMOR MARKER;

ANTIBODY LABELING; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; CELL STRAIN MCF 7 VP; CELL STRAIN MCF 7 WT; DRUG ACCUMULATION; DRUG UPTAKE; HUMAN; HUMAN CELL; HYPOXIA; PROTEIN EXPRESSION; BREAST TUMOR; CELL HYPOXIA; COMPARATIVE STUDY; EVALUATION; METABOLIC CLEARANCE RATE; METABOLISM; SCINTISCANNING; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; METABOLIC CLEARANCE RATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; OXYGEN; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M SESTAMIBI; TUMOR MARKERS, BIOLOGICAL;

EID: 0242323759     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1268-0     Document Type: Article

References (10)

1. Ballinger JR. Imaging multidrug resistance with radiolabeled substrates for P-glycoprotein and multidrug resistance protein. Cancer Biother Radiopharm 2001; 16:1-7.
2. Kuwano M, Uchiumi T, Hayakawa H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 2003; 94:9-14.
3. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Evaluation of radiotherapeutic response in non-small cell lung cancer patients by technetium-99m MIBI and thallium-201 chloride SPET. Eur J Nucl Med 2000; 27:536-541.
4. Moretti, J-L, Azaloux H, Boisseron D, Kouyoumdjian J-C, Vilcoq J. Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression. Eur J Nucl Med 1996; 23:980-986.
5. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93:266-276.
6. 99mTc-HL91. Eur J Nucl Med Mol Imaging 2002; 29:1006-1011.
7. Sakata K, Kwok TT, Murphy BJ, Laderoute KR, Gordon GR, Sutherland RM. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 1991; 64:809-814.
8. Diah SK, Smitherman PK, Aldridge J, et al. Resistance of mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transporter and the role of multidrug resistance protein family proteins. Cancer Res 2001; 61:5461-5467.
9. Arbab AS, Koizumi K, Toyama K, Arai T, Araki T. Technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 uptake in rat myocardial cells. J Nucl Med 1998; 39:266-271.
10. 99mTc-hexakis-2-methoxyisobutyl isonitrile SPECT. J Nucl Med 1999; 40:1778-1783.